Neutralizing and cross-reacting antibodies: implications for immunotherapy and SARS-CoV-2 vaccine development
The novel coronavirus SARS-CoV-2 emerged in China in 2019 and quickly spread globally, causing a pandemic. There is an urgent need to develop vaccines against the virus, and both convalescent plasma and immune globulin are currently in clinical trials for treatment of patients with COVID-19. It is u...
Saved in:
Main Authors: | Samuel A. Cohen (Author), Caitlyn Kellogg (Author), Ozlem Equils (Author) |
---|---|
Format: | Book |
Published: |
Taylor & Francis Group,
2021-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The role of the thymus in COVID-19 disease severity: implications for antibody treatment and immunization
by: Caitlyn Kellogg, et al.
Published: (2021) -
Neutralizing and enhancing antibodies against SARS-CoV-2
by: Yafei Liu, et al.
Published: (2022) -
Emerging SARS-CoV-2 variants: impact on vaccine efficacy and neutralizing antibodies
by: Khan Sharun, et al.
Published: (2021) -
Neutralizing Antibody Response by Inactivated SARS-CoV-2 Vaccine on Healthcare Workers
by: Nataniel Tandirogang, et al.
Published: (2023) -
Potent SARS-CoV-2 binding and neutralization through maturation of iconic SARS-CoV-1 antibodies
by: Romain Rouet, et al.
Published: (2021)